Will This Obesity Biotech's Latest Scheme Boost Sales?
Drugmaker VIVUS (NASDAQ: VVUS ) has struggled to ramp up sales of its recently approved obesity medication Qsymia. With competition from Arena Pharmaceuticals (NASDAQ: ARNA ) and its partner Eisai (NASDAQOTH: ESALY ) looming once their drug Belviq clears DEA scheduling, VIVUS has launched the Save Now! program. In this video, health care analyst Max Macaluso discusses how this new program will impact VIVUS' business and how it might affect the competitive landscape of the obesity market.
VVUS is the one doing the pricing scheme and clearly VVUS is dropping their pants and are scared to death of Belviq hitting the market. I am sure they have pulled every rabbit out of the hat and called in every marker to stall Arena. Don't kid yourself these guys are very well connected.